The specificity of antibodies can be exploited therapeutically.
Therapeutic immunoglobulins can be derived from a number of sources. In addition to human-derived, recombinant immunoglobulins have superceded many animal-derived immunoglobulins. Recombinant biotechnology also allows fusion of animal-derived immunoglobulins to human components (see below).
Unfractionanted, human-derived immunoglobulin can be given as normal immunoglobulin. This is the immunoglobulin fraction of blood isolated and pooled from several hundred blood donors.
More frequently, specific immunoglobulins are isolated and used to neutralise specific targets.
People with no previous exposure to certain antigens will have no immune memory. The process of producing effective antibodies takes a minimum of 3 weeks, often longer. If immediate protection is required during this period, the patient may acquire passive immunisation by receiving immunoglobulins from another source, usually pooled antibodies from human blood donation and, less commonly now, animal anti-sera. Below are several examples of antigens that may required immediate protection.
For various scientific, ethical and safety reasons, it is not possible to use humans to produce antibodies. Instead, the part of the antibody that recognises the antigen is often developed in animals and then 'humanised' by adding the human Fc portion of immunoglobulin through recombinant technology. Thes are usually prepared as.
This category has the following 5 subcategories, out of 5 total.
Pages in category "Therapeutic antibody"
The following 50 pages are in this category, out of 50 total.